Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David E. Gunn is active.

Publication


Featured researches published by David E. Gunn.


Bioorganic & Medicinal Chemistry Letters | 2001

p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas.

Aniko Redman; Jeffrey S Johnson; Robert Dally; Steve Swartz; Hanno Wild; Holger Paulsen; Yolanda V Caringal; David E. Gunn; Joel Renick; Martin Osterhout; Jill Kingery-Wood; Roger A. Smith; Wendy Lee; Jacques Dumas; Scott Wilhelm; Timothy J Housley; Ajay Bhargava; Gerald Ranges; Alka Shrikhande; Deborah Young; Michael Bombara; William J. Scott

Inhibitors of the MAP kinase p38 are potentially useful for the treatment for osteoporosis, arthritis, and other inflammatory diseases. A series of thienyl, furyl, and pyrrolyl ureas has been identified as potent p38 inhibitors, displaying in vitro activity in the nanomolar range.


Bioorganic & Medicinal Chemistry Letters | 1998

Synthesis and structure-activity relationships of pyridine-modified analogs of 3-[2-((S)-pyrrolidinyl)methoxy]pyridine, A-84543, a potent nicotinic acetylcholine receptor agonist

Nan-Horng Lin; David E. Gunn; Yihong Li; Yun He; Hao Bai; Keith B. Ryther; Theresa A. Kuntzweiler; Diana L. Donnelly-Roberts; David J. Anderson; Jeffrey E. Campbell; James P. Sullivan; Stephen P. Arneric; Mark W. Holladay

Analogs of 3-[2-((S)-pyrrolidinyl)methoxy]pyridine, (A-84543, 1) with 2-, 4-, 5-, and 6-substituents on the pyridine ring were synthesized. These analogs exhibited Ki values ranging from 0.15 to > 9,000 nM when tested in vitro for neuronal nicotinic acetylcholine receptor binding activity. Assessment of functional activity at subtypes of neuronal nicotinic acetylcholine receptors indicates that pyridine substitution can have a profound effect on efficacy at these subtypes, and several subtype-selective agonists and antagonists have been identified.


Bioorganic & Medicinal Chemistry Letters | 1996

2-(Aryloxymethyl) azacyclic analogues as novel nicotinic acetylcholine receptor (nAChR) ligands

Richard L. Elliott; Hana Kopecka; David E. Gunn; Nan-Horng Lin; David S. Garvey; Keith B. Ryther; Mark W. Holladay; David J. Anderson; Jeffrey E. Campbell; James P. Sullivan; Michael J. Buckley; Karen L. Gunther; Alyssa B. O'Neill; Michael W. Decker; Stephen P. Arneric

Abstract A series of 2-(aryloxymethyl) azetidine and pyrrolidine nAChR ligands in which the 3-pyridyl moiety of a previously described series 1 was replaced by a substituted phenyl group was explored. Aromatic substitution afforded analogues with K i values ranging from 3 to >10,000 nM. Generally, substitution at the ortho - and para -position was unfavorable, whereas electron-withdrawing groups at the meta -position improved the K i values.


Bioorganic & Medicinal Chemistry Letters | 1999

Structure-activity studies on a novel series of cholinergic channel activators based on a heteroaryl ether framework.

Nan-Horng Lin; Melwyn Abreo; David E. Gunn; Suzanne A. Lebold; Edmund L. Lee; James T. Wasicak; Ann-Marie Hettinger; Jerome F. Daanen; David S. Garvey; Jeffrey E. Campbell; James P. Sullivan; Michael D. Williams; Stephen P. Arneric

Analogs of compound 1 with a variety of azacycles and heteroaryl groups were synthesized. These analogs exhibited Ki values ranging from 0.15 to > 10,000 nM when tested in vitro for cholinergic channel receptor binding activity (displacement of [3H](-) cytisine from whole rat brain synaptic membranes).


Journal of Medicinal Chemistry | 1996

Novel 3-pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors

Melwyn Abreo; Nan-Horng Lin; David S. Garvey; David E. Gunn; Ann-Marie Hettinger; James T. Wasicak; Patricia A. Pavlik; Yvonne C. Martin; Diana L. Donnelly-Roberts; David J. Anderson; James P. Sullivan; Michael T. Williams; Stephen P. Arneric; Mark W. Holladay


Archive | 1998

INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS

Scott Miller; Martin Osterhout; Jacques Dumas; Uday Khire; Timothy B. Lowinger; William J. Scott; Roger A. Smith; Jill E. Wood; David E. Gunn; Holia Hatoum-Mokdad; Marell Rodriguez; Robert Sibley; Ming Wang; Tiffany Turner; Catherine Brennan


Archive | 1998

Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas

Scott Miller; Martin Osterhout; Jacques Dumas; Uday Khire; Timothy B. Lowinger; Bernd Riedl; William J. Scott; Roger A. Smith; Jill E. Wood; David E. Gunn; Ming Wang; Tiffany Turner; Catherine Brennan


Archive | 2002

Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas

Jacques Dumas; Bernd Riedl; Uday Khire; Robert Sibley; Holia Hatoum-Mokdad; Mary-Katherine Monahan; David E. Gunn; Timotthy B. Lowinger; William J. Scott; Roger A. Smith; Jill E. Wood


Archive | 1993

Heterocyclic ether compounds that enhance cognitive function

Melwyn Abreo; David E. Gunn; Nan-Horng Lin; Richard L. Elliott; David S. Garvey; Suzanne A. Lebold; James T. Wasicak


Journal of Pharmacology and Experimental Therapeutics | 1997

ABT-089 [2-Methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A Potent and Selective Cholinergic Channel Modulator with Neuroprotective Properties

James P. Sullivan; Diana L. Donnelly-Roberts; Clark A. Briggs; David J. Anderson; Murali Gopalakrishnan; Iris C. Xue; Marietta Piattoni-Kaplan; Eduardo J. Molinari; Jeffrey E. Campbell; David G. McKenna; David E. Gunn; Nan-Horng Lin; Keith B. Ryther; Yun He; Mark W. Holladay; Susan Wonnacott; Michael Williams; Stephen P. Arneric

Collaboration


Dive into the David E. Gunn's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge